Loading...
Market
Story
Merck Licenses Cancer Antibody from Closely Held Chinese Firm LaNova in $588 Million Deal, Up to $2.7B
Nov 14, 2024, 11:48 AM
Merck & Co. has entered into an exclusive global licensing agreement with the closely held Chinese company LaNova Medicines Ltd. to develop, manufacture, and commercialize LM-299, an investigational anti-PD-1/VEGF bispecific antibody. This deal includes an upfront payment of $588 million, with potential milestone payments that could total up to $2.7 billion. The agreement is part of Merck's strategic efforts to bolster its therapeutic pipeline as it faces a significant loss of exclusivity (LOE) for its blockbuster drug Keytruda, projected to result in a $30 billion revenue loss by 2028. This move aligns with the broader trend in the pharmaceutical industry where companies ramp up mergers and acquisitions as they approach major LOEs.
View original story
Similar markets
Weight Reduction • 25%
Cardiovascular Benefits • 25%
Diabetes Management • 25%
Other • 25%
Mesothelioma • 25%
Lung Cancer • 25%
Breast Cancer • 25%
Other • 25%
Breast cancer • 25%
Lung cancer • 25%
Colorectal cancer • 25%
Other cancer types • 25%
Diabetic Macular Edema • 25%
Metabolic Liver Dysfunction • 25%
Addiction Treatment • 25%
Other • 25%
Johnson & Johnson • 25%
Pfizer • 25%
AstraZeneca • 25%
Roche • 25%
US only • 25%
US and EU • 25%
US, EU, and China • 25%
None • 25%
SMA Type 3 • 25%
SMA Type 2 • 25%
Both SMA Type 2 and 3 • 25%
Other • 25%
Approved in USA only • 25%
Approved in EU only • 25%
Approved in both USA and EU • 25%
Not approved in USA or EU • 25%
Merck & Co. • 25%
AstraZeneca • 25%
Roche • 25%
Other • 25%
Advanced Synovial Sarcoma • 25%
Other Sarcomas • 25%
Other Solid Tumors • 25%
Combination Therapies • 25%